Paltusotine: A Step Toward Precision Medicine in Acromegaly

Affiliations

¹ Department of Endocrinology, Centre de Référence des Maladies Rares hypophysaires HYPO, Hôpital La Conception, Aix Marseille Univ, INSERM, UMR1251, Marseille Medical Genetics, Institut MarMaRa, and APHM, 13385 Marseille, France.

Editorial

Frederic Castinetti et al. J Clin Endocrinol Metab. 2025.

. 2025 Feb 18;110(3):e897-e898.

doi: 10.1210/clinem/dgae489.

¹ Department of Endocrinology, Centre de Référence des Maladies Rares hypophysaires HYPO, Hôpital La Conception, Aix Marseille Univ, INSERM, UMR1251, Marseille Medical Genetics, Institut MarMaRa, and APHM, 13385 Marseille, France.

No abstract available

Keywords: acromegaly; lanreotide; octreotide; pituitary; somatostatin.

Comment on

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.
Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, Boguszewski CL, Buchfelder M, Shimon I, Raverot G, Tóth M, Mezősi E, Doknic M, Fan X, Clemmons D, Trainer PJ, Struthers RS, Krasner A, Biller BMK. Gadelha MR, et al. J Clin Endocrinol Metab. 2024 Dec 18;110(1):228-237. doi: 10.1210/clinem/dgae385. J Clin Endocrinol Metab. 2024. PMID: 38828555 Free PMC article. Clinical Trial.